Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05AH06
|
| gptkbp:brand |
Caplyta
|
| gptkbp:CASNumber |
951376-59-1
|
| gptkbp:chemicalClass |
isoquinolinone derivative
|
| gptkbp:developer |
Intra-Cellular Therapies, Inc.
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C24H28FN3O
|
| https://www.w3.org/2000/01/rdf-schema#label |
lumateperone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist dopamine D1 receptor modulator serotonin transporter inhibitor |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
weight gain dry mouth somnolence increased creatinine |
| gptkbp:usedFor |
schizophrenia
bipolar depression |
| gptkbp:bfsParent |
gptkb:N05AX
|
| gptkbp:bfsLayer |
7
|